MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance
Yonghua Sheng, Choa Ping Ng, Rohan Lourie, Esha T Shah, Yaowu He, Kuan Yau Wong, Inge Seim, Iulia Oancea, Christudas Morais, Penny L Jeffery, John Hooper, Glenda C Gobe, Michael A McGuckin
INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2017
Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective. Here we reveal that MUC13, a cell surface mucin glycoprotein, is aberrantly expressed by most renal cell carcinomas, with increasing expression positively correlating with tumor grade. Importantly, we demonstrated that high MUC13 expression was a statistically significant independent predictor of poor survival in two independent cohorts, particularly in stage 1 cancers. In cultured renal cell carcinoma cells MUC13 promoted proliferation and induced the cell cycle regulator, cyclin D1, and inhibited apoptosis by inducing the..View full abstract
Awarded by NHMRC
Grant sponsor: This work was supported by NHMRC project grant 1060698 and by funding from the Mater Foundation, MAM is supported by a NHMRC Senior Research Fellowship. RL was partly supported by a Betty McGrath/Mater Practitioner Research Fellowship. IS is supported by a QUT Vice-Chancellor's Senior Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government.